Low-molecular-weight heparin during pregnancy.
Thromboembolism is an infrequent, yet serious cause of both maternal and fetal morbidity and death during pregnancy and the puerperium. Pregnancy itself increases the risk of thromboembolic complications probably owing to a combination of hypercoagulability and venous stasis due to venous dilation. Recent studies have indicated that some serious obstetric complications are correlated with inherited or acquired thrombophilia. The prevalence of venous thromboembolism (VTE) has been extimated to be 1 per 1000-2000 pregnancies in retrospective studies. Anticoagulant treatment and prophylaxis both before and during pregnancy are based on unfractionated heparin (UH), low-molecular-weight heparin (LMWH) and warfarin. Warfarin is teratogenous if administered between the 6th and the 12th week. LMWH is replacing UH in the prevention and treatment of VTE both outside and more recently during pregnancy with the same indications, and also for obstetric complications. This paper assesses the safety and efficacy of heparin therapy during pregnancy and the puerperium. Its cardiovascular and obstetric indications and regimens and maternal and fetal side-effects are also discussed.